Senate Passes Historic Bill that Would Let Medicare Negotiate Some Drugs’ Prices

Sen. Chuck Schumer (D-NY) speaking on Senate floor
Senate Majority Leader Chuck Schumer (D-N.Y.) opens debate Sunday on historic legislation that would let Medicare negotiate prices on a small number of high-cost single-source drugs. The House is expected to pass the bill this Friday.

The U.S. Senate on Sunday passed historic legislation to let Medicare negotiate the prices of a small number of costly medicines and require drug manufacturers to pay Medicare rebates when prices paid by Medicare rise faster than inflation.

Language in

Read More »

Vermont Passes Bill Enhancing 340B Anti-Discriminatory Protections but Measure Aimed at Drug Manufacturers Fails

Vermont State House building
Vermont recently extended its prohibition on discrimination by PBMs against 340B entities but did not require drug manufacturers to provide 340B-priced drugs to contract pharmacies.

The state of Vermont has passed a bill extending its prohibition on discrimination by pharmacy benefit managers (PBMs) against 340B covered entities, which was originally passed in June 2021 as part of the state’s 2022 budget. 

The bill was quietly

Read More »

Providers March on U.S. Capitol Grounds to “Defend 340B”

340B program advocates with signs in front of the US Capitol building
Safety-net provider advocates marched on the U.S. Capitol grounds yesterday to raise awareness about threats to the 340B drug pricing program.

About 100 safety-net provider advocates marched and chanted yesterday on the grounds of the U.S. Capitol to raise awareness in Congress and beyond about threats to the 340B drug pricing program.

The demonstration, organized by Community Voices for 340B (CV340B),

Read More »

Senate Democrats Say They Are on Track to Pass Drug Pricing Bill Before Aug. 8

U.S. Senate chamber viewed from public gallery
Senate Democrats are still pushing to pass drug pricing legislation before the chamber begins its summer break on Aug. 8.

Senate Democrats said yesterday they would know this week whether an updated Senate drug pricing bill meets the criteria for passage via budget reconciliation, which requires just 50 Democratic votes. The bill remains on track for a floor vote before

Read More »

340B Report Publisher and CEO: What to Expect Following Midterm Elections

A roll of I Voted, Yo Vote stickers
Look for the GOP to try again to put more restrictions on the 340B program if the party takes over the U.S. House, 340B Report Publisher and CEO Ted Slafsky says.

Congress’ attitude toward the 340B program will likely change in 2023 and 2024 because of November’s midterm election results, 340B Report Publisher and CEO Ted Slafsky predicts in his latest column for Omnicell.

It is customary for the party that

Read More »

Senate Democrats Optimistic About Passing Drug Pricing Bill Before August Recess

Rachel Cohrs and Sen. Ron Wyden headshots
Senate Finance Chair Ron Wyden (right) said yesterday during a webinar moderated by STAT correspondent Rachel Cohrs (left) that Senate Democrats want to pass drug pricing legislation "right now, before everybody leaves for August."

U.S. Senate Democrats are hopeful that drug pricing legislation will be passed by early next month via a budget reconciliation process requiring just 50 Democratic votes, a Democratic source with knowledge of the process told 340B Report.

“Our expectation is, we’re

Read More »

News Alert

181 House Members Prod HHS to Start Fining Drug Makers for “Unlawful” 340B Overcharges Involving Contract Pharmacies

East elevation of the U.S. Capitol building
181 bipartisan U.S. House members on Friday urged HHS to quickly fine all drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.

One hundred eighty-one U.S. House members—144 Democrats and 37 Republicans—urged the Biden administration on Friday to quickly impose civil monetary penalties against all drug manufacturers that restrict access to 340B pricing when covered entities use contract pharmacies.

“Manufacturers have received

Read More »

House GOP Task Force Apparently Takes a Pass on Making 340B Recommendations

Rep. Kevin Hern (R-OK) seated
A House GOP task force subcommittee chaired by Rep. Kevin Hern (R-Okla.) apparently has decided not to recommend 340B policies the party can advance if its takes control of the House following the November elections.

A U.S. House Republican task force assigned to develop proposals the party can advance if the GOP takes the majority in the November elections apparently chose not to make recommendations for the 340B program.

The Healthy Future Task Force’s affordability

Read More »

Senate Democratic Drug Pricing Bill Buoyed by Large Savings Estimate

Congressional Budget Office logo
Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.

U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over 10 years, the nonpartisan Congressional Budget Office said late last week.

Last November, CBO estimated that drug pricing language in the House-passed Build Back

Read More »

Analysts Still Digesting Senate Democratic Drug Pricing Bill’s 340B Changes

digital image of hand holding cash and hand holding pharmaceuticals
Covered entities are studying how a new drug pricing bill would affect access to 340B pricing on drugs subject to Medicare price negotiation.

If Congress votes to gives Medicare the power to negotiate some drug prices, drug manufacturers would not have to provide price concessions that exceed the lower of a drug’s 340B price or the Medicare negotiated price, according to a summary

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live